Narcolepsy Drugs Market Size, Share, Growth Analysis, By Narcolepsy Type(Cataplexy, and Daytime Extreme Sleepiness.), By Therapeutics(Psychostimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitors), By End User(Hospitals, and Diagnostic Centres. ), By Region - Industry Forecast 2024-2031

Global Narcolepsy Drugs Market is expected to rise from USD 3.21 billion in 2022 and rise from USD 3.52 billion in 2023 to reach USD 7.32 billion by 2031, by rising at a CAGR of 9.60% during the forecast period (2024- 2031).

The market is primarily driven by the aging population, and their vulnerability to various chronic and acute diseases that require medical care.The rise in narcoleptic diseases, changing lifestyles, and the rise in stress levels, which cause narcolepsy disorder are also projected to aid in market expansion during the forecast period. Furthermore, the narcolepsy therapeutics market is projected to witness significant growth in the coming years owing to increase in research efforts, rise in healthcare expenditure,, and the presence of enhanced medical infrastructure.

The symptoms of central hypersomnia can be controlled by circadian delay, more sleep, and teleworking. Due to the low consumption of narcolepsy treatments and the public's desire for better sleep circumstances, the narcolepsy drugs market is projected to witness significant growth in the coming years.

On the other hand, high expenses and a lack of knowledge about the availability of treatment for narcolepsy may limit market expansion in the future. In addition to this, high treatment and diagnostic costs as well as an unfavourable reimbursement environment are the factors that will restrain market expansion. The narcolepsy treatment market would face challenges throughout the forecast period due to decreased operating revenue opportunities for targeted therapy research and development by various pharmaceuticals.

US Narcolepsy Drugs Market  is poised to grow at a sustainable CAGR for the next forecast year.